Q-LINEA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.295 SEK | +64.91% |
|
+59.56% | -10.95% |
| 03-13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
| 02-27 | Transcript : Q-linea AB, Q4 2023 Earnings Call, Feb 27, 2024 |
| Sales 2024 * | 60.55M 5.53M 443M | Sales 2025 * | 167M 15.25M 1.22B | Capitalization | 385M 35.19M 2.82B |
|---|---|---|---|---|---|
| Net income 2024 * | -191M -17.46M -1.4B | Net income 2025 * | -146M -13.35M -1.07B | EV / Sales 2024 * | 4.16 x |
| Net cash position 2024 * | 133M 12.19M 976M | Net cash position 2025 * | 5.88M 537K 43.01M | EV / Sales 2025 * | 2.27 x |
| P/E ratio 2024 * |
-2.71
x | P/E ratio 2025 * |
-4.02
x | Employees | 127 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Q-linea AB
| 1 day | +64.91% | ||
| 1 week | +59.56% | ||
| Current month | +53.97% | ||
| 1 month | +53.26% | ||
| 3 months | -0.15% | ||
| 6 months | +13.23% | ||
| Current year | -10.95% |
1 week
1.95
3.79
1 month
1.953.79
Current year
1.953.86
1 year
1.9510.30
3 years
1.95164.00
5 years
1.95187.50
10 years
1.95187.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 53 | 31/03/08 | |
| Director of Finance/CFO | 70 | 30/04/23 | |
Henrik Jacobsson
COO | Chief Operating Officer | 55 | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 31/12/11 | |
| Founder | 54 | 31/03/08 | |
| Director/Board Member | 70 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.295 | +64.91% | 7,994,951 |
| 25/04/24 | 1.998 | -0.60% | 80,382 |
| 24/04/24 | 2.01 | +0.50% | 59,230 |
| 23/04/24 | 2 | -3.85% | 68,233 |
| 22/04/24 | 2.08 | +0.73% | 128,996 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Calendar
03/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.95% | 35.11M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- QLINEA Stock
